UNSPSC 51401549: Haloxazolam

This classification denotes a benzodiazepine with the molecular formula C17H14BrFN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M448L2V8XP, chemically known as 10-bromo-11b-(o-fluorophenyl)-2,3,7,11b-tetrahydrooxazolo(3,2-d)(1,4)benzodiazepin-6(5h)-one but generally known as haloxazolam, which bears US NIH Compound Identifier 3563. European Medicines Agency schedules Haloxazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08010MIG.

UNSPSC 51401549 Haloxazolam is a Commodity-level code that does not align with the recent state and local opportunities posted under it. The three most recent solicitations—from Seminole County (naloxone and drug deactivation systems), Texas HHS (therapeutic pharmacy direct-to-manufacturer initiatives), and Minnesota MMCAP (generic multi-source pharmaceuticals and OTC products)—address pharmaceutical procurement broadly but do not target haloxazolam specifically. The Seminole County opportunity seeks naloxone, a distinct medication used for opioid overdose reversal, while the Texas and Minnesota solicitations cover pharmacy benefit programs and generic pharmaceutical supply chains without naming haloxazolam as a line item. The code shows little relevant recent activity; the mismatch between the haloxazolam commodity designation and the actual pharmaceutical procurement scope evident in recent notices suggests either miscoding of opportunities or minimal current demand for haloxazolam specifically through state and local channels.

The geographic spread of recent opportunities spans Florida (Seminole County), Texas (HHS Commission), and Minnesota (MMCAP cooperative purchasing). The issuing bodies represent county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. The Seminole County IFB (due July 26, 2023) and Minnesota MMCAP RFP (due March 26, 2026) represent direct product procurement, while the Texas HHS RFI (posted April 3, 2026) is exploratory market research on pharmacy benefit structures. None of these opportunities name haloxazolam among the products or therapeutic categories being solicited, limiting the relevance of this code for vendors focused specifically on that medication.